Italy's Newron Pharmaceuticals has begun its second Phase III trial of safinamide for Parkinson's disease. The study, to be conducted with Serono, will examine improvements in functioning. Serono gained worldwide marketing rights to safinamide in October. Newron has also set a price range of 45 to 60 sfr when it launches its IPO on December 12.
- check out the the AFX report [1] on the new clinical trial
- read the report [2] on the IPO
Related Article:
Serono licenses Newron Parkinson's therapy. Report [3]
Merck KGaA buying control of Serono. Report [4]
Links:
[1] http://www.forbes.com/business/feeds/afx/2006/11/27/afx3204411.html
[2] http://www.forbes.com/business/feeds/afx/2006/11/27/afx3204391.html
[3] http://www.fiercebiotech.com/story/serono-licenses-newron-parkinson-s-therapy/2006-10-16
[4] http://www.fiercebiotech.com/story/merck-kgaa-buying-control-of-serono/2006-09-21